Your browser is no longer supported. Please, upgrade your browser.
Settings
RARE [NASD]
Ultragenyx Pharmaceutical Inc.
Index- P/E- EPS (ttm)-5.29 Insider Own1.80% Shs Outstand67.88M Perf Week-1.16%
Market Cap5.09B Forward P/E- EPS next Y-5.71 Insider Trans-1.96% Shs Float65.10M Perf Month-6.32%
Income-355.60M PEG- EPS next Q-1.30 Inst Own98.80% Short Float5.68% Perf Quarter-18.58%
Sales359.60M P/S14.15 EPS this Y56.90% Inst Trans0.63% Short Ratio9.59 Perf Half Y-24.80%
Book/sh13.76 P/B5.56 EPS next Y14.70% ROA-22.40% Target Price142.00 Perf Year-36.17%
Cash/sh11.08 P/C6.90 EPS next 5Y17.20% ROE-34.60% 52W Range74.11 - 179.65 Perf YTD-44.74%
Dividend- P/FCF- EPS past 5Y5.00% ROI-28.70% 52W High-57.42% Beta1.64
Dividend %- Quick Ratio6.10 Sales past 5Y- Gross Margin95.00% 52W Low3.21% ATR3.06
Employees893 Current Ratio6.20 Sales Q/Q0.10% Oper. Margin- RSI (14)36.77 Volatility4.19% 4.07%
OptionableYes Debt/Eq0.00 EPS Q/Q5.20% Profit Margin-98.90% Rel Volume0.58 Prev Close77.58
ShortableYes LT Debt/Eq0.00 EarningsNov 02 AMC Payout- Avg Volume385.52K Price76.49
Recom2.20 SMA20-5.96% SMA50-9.06% SMA200-23.19% Volume224,532 Change-1.41%
Sep-30-21Initiated H.C. Wainwright Buy $106
Aug-19-21Initiated UBS Sell $73
Jul-15-21Initiated Guggenheim Neutral
Jun-29-21Upgrade BofA Securities Neutral → Buy $162
Jun-04-21Resumed Robert W. Baird Neutral $109
May-06-21Upgrade Evercore ISI In-line → Outperform $144
May-06-21Upgrade Citigroup Neutral → Buy $160 → $151
Apr-26-21Resumed Credit Suisse Neutral $99
Mar-02-21Resumed Stifel Buy $179
Feb-12-21Downgrade JP Morgan Overweight → Neutral $165
Dec-07-20Downgrade Wedbush Outperform → Neutral $105 → $110
Nov-24-20Resumed Evercore ISI In-line $110
Nov-12-20Downgrade BofA Securities Buy → Neutral $104 → $126
Aug-02-19Resumed Wedbush Outperform $75
Mar-27-19Upgrade Morgan Stanley Equal-Weight → Overweight $68 → $83
Feb-22-19Resumed Raymond James Outperform $80
Jan-02-19Downgrade Raymond James Outperform → Mkt Perform
Nov-08-18Upgrade Citigroup Sell → Neutral
Sep-10-18Initiated Morgan Stanley Equal-Weight $92
Jun-21-18Downgrade Credit Suisse Outperform → Neutral
Nov-17-21 03:07PM  
Nov-03-21 11:56AM  
12:01AM  
Nov-02-21 05:25PM  
04:05PM  
Oct-26-21 04:05PM  
Oct-25-21 04:05PM  
Oct-19-21 03:02PM  
Oct-18-21 12:21PM  
08:00AM  
Oct-15-21 10:25AM  
Oct-08-21 10:48AM  
Oct-07-21 08:00AM  
Oct-04-21 04:05PM  
Oct-01-21 04:31PM  
Sep-28-21 12:24PM  
Sep-27-21 04:30PM  
10:39AM  
08:00AM  
Sep-10-21 04:49PM  
Sep-09-21 03:00AM  
Sep-07-21 04:30PM  
08:00AM  
Sep-01-21 04:30PM  
11:30AM  
Aug-31-21 09:19AM  
Aug-23-21 08:30AM  
Aug-17-21 04:05PM  
Aug-13-21 10:53AM  
Aug-04-21 08:30AM  
Aug-03-21 01:22PM  
08:30AM  
Aug-02-21 05:35PM  
04:05PM  
Jul-27-21 05:00PM  
08:00AM  
Jul-22-21 03:03PM  
Jul-13-21 01:16PM  
03:30AM  
Jun-30-21 08:30AM  
Jun-18-21 10:47AM  
Jun-10-21 08:30AM  
Jun-03-21 04:01PM  
11:31AM  
Jun-02-21 06:02AM  
May-26-21 08:31AM  
May-19-21 08:30AM  
May-18-21 04:05PM  
May-14-21 02:33PM  
08:30AM  
May-10-21 04:01PM  
09:02AM  
May-05-21 07:52AM  
06:01AM  
May-04-21 05:35PM  
04:01PM  
03:15PM  
Apr-28-21 04:01PM  
12:34PM  
08:31AM  
Apr-27-21 05:47PM  
Apr-22-21 08:30AM  
Apr-20-21 06:49PM  
Apr-05-21 08:00AM  
Mar-13-21 11:30AM  
Mar-09-21 01:16PM  
09:31AM  
06:35AM  
Mar-08-21 08:30AM  
Mar-04-21 02:48AM  
Mar-03-21 08:31AM  
Feb-27-21 09:23AM  
Feb-19-21 07:17AM  
Feb-17-21 04:01PM  
08:30AM  
Feb-12-21 10:09AM  
Feb-11-21 10:31PM  
05:45PM  
04:25PM  
04:05PM  
03:15PM  
Feb-04-21 08:31AM  
Jan-22-21 09:02AM  
Jan-21-21 08:30AM  
Jan-12-21 10:04AM  
Jan-11-21 07:00AM  
Jan-08-21 09:00AM  
Jan-05-21 08:31AM  
Jan-04-21 09:34AM  
Dec-28-20 06:42AM  
Dec-18-20 11:15AM  
Dec-17-20 05:25PM  
04:05PM  
04:05PM  
Dec-14-20 04:15PM  
Dec-10-20 09:40AM  
Dec-09-20 04:05PM  
Dec-05-20 01:00PM  
Nov-24-20 08:31AM  
Nov-09-20 08:05AM  
Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in the United States. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; and Dojolvi for treating long-chain fatty acid oxidation disorders. The company is also developing DTX401, an adeno-associated virus 8 (AAV8) gene therapy clinical candidate for the treatment of patients with glycogen storage disease type Ia; DTX301, an AAV8 gene therapy product candidate for the treatment of patients with ornithine transcarbamylase; UX143, a human monoclonal antibody for the treatment of osteogenesis imperfecta; GTX-102, an antisense oligonucleotide for the treatment of Angelman syndrome; UX701, for the treatment of Wilson disease; and UX053 for the treatment of glycogen storage disease type III. Ultragenyx Pharmaceutical Inc. has collaboration and license agreement with Kyowa Kirin Co., Ltd.; Saint Louis University; Baylor Research Institute; REGENXBIO Inc.; Bayer; GeneTx; Mereo; University of Pennsylvania; Arcturus Therapeutics Holdings Inc., Solid Biosciences Inc.; and Daiichi Sankyo Co., Ltd. Ultragenyx Pharmaceutical Inc. was incorporated in 2010 and is headquartered in Novato, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Dier MardiCFO & Executive Vice PresidentOct 14Sale81.163,261264,66338,762Oct 14 06:33 PM
Bedrosian Camille LEVP and Chief Medical OfficerOct 14Sale81.1435929,12938,416Oct 18 07:02 PM
Harris ErikEVP & Chief Commercial OfficerOct 14Sale81.1430324,58525,030Oct 18 06:58 PM
Huang Dennis KarlEVP & Chief Tech Ops OfficerOct 14Sale81.1435829,04840,148Oct 18 06:55 PM
Huizenga Theodore AlanSVP, Chief Accounting OfficerOct 14Sale81.1414011,36014,072Oct 18 06:53 PM
Kassberg Thomas RichardCBO & EVPOct 14Sale81.1428623,206216,266Oct 18 06:48 PM
Parschauer Karah HerdmanEVP and General CounselOct 14Sale81.1431025,15328,358Oct 18 06:46 PM
Pinion John RichardSee RemarksOct 14Sale81.1435829,04849,764Oct 18 06:41 PM
Dier MardiCFO & Executive Vice PresidentOct 12Sale82.793,477287,86142,023Oct 14 06:33 PM
Kassberg Thomas RichardCBO & EVPSep 30Option Exercise0.31109,73434,018216,552Oct 01 12:57 PM
Parschauer Karah HerdmanEVP and General CounselSep 08Option Exercise54.507,336399,81236,004Sep 09 06:22 PM
Parschauer Karah HerdmanEVP and General CounselSep 08Sale100.657,336738,36828,668Sep 09 06:22 PM
Bedrosian Camille LEVP and Chief Medical OfficerSep 02Option Exercise55.002,500137,50041,275Sep 02 06:11 PM
Bedrosian Camille LEVP and Chief Medical OfficerSep 02Sale100.182,500250,45038,775Sep 02 06:11 PM
Bedrosian Camille LEVP and Chief Medical OfficerSep 01Option Exercise55.002,500137,50041,275Sep 02 06:11 PM
Bedrosian Camille LEVP and Chief Medical OfficerSep 01Sale100.032,500250,07538,775Sep 02 06:11 PM
Harris ErikEVP & Chief Commercial OfficerJul 06Sale91.5337534,32425,333Jul 08 11:56 AM
Harris ErikEVP & Chief Commercial OfficerJun 21Sale94.9657254,31725,708Jun 23 05:55 PM
Harris ErikEVP & Chief Commercial OfficerJun 19Sale94.6343741,35326,280Jun 23 05:55 PM
Parschauer Karah HerdmanEVP and General CounselJun 10Sale100.001,329132,90028,668Jun 11 09:08 PM
Harris ErikEVP & Chief Commercial OfficerMay 07Sale113.6739344,67226,717May 10 06:10 PM
Huang Dennis KarlEVP & Chief Tech Ops OfficerMay 06Sale113.6836341,26640,506May 10 06:14 PM
Pinion John RichardSee RemarksMay 06Sale113.6936341,26950,122May 10 06:13 PM
Parschauer Karah HerdmanEVP and General CounselMay 06Sale113.6731335,57929,997May 10 06:13 PM
Kassberg Thomas RichardCBO & EVPMay 06Sale113.6936341,269106,818May 10 06:11 PM
Huizenga Theodore AlanSVP, Chief Accounting OfficerMay 06Sale113.6714216,14115,031May 10 06:12 PM
Bedrosian Camille LEVP and Chief Medical OfficerMay 06Sale113.6736441,37638,775May 10 06:09 PM
Harris ErikEVP & Chief Commercial OfficerMay 06Sale113.6830734,90027,110May 10 06:10 PM
KAKKIS EMIL DPresident & CEOMay 03Sale107.8030,0003,234,0002,259,741May 05 11:32 AM
Harris ErikEVP & Chief Commercial OfficerApr 20Sale104.2839641,29527,417Apr 21 08:07 PM
Bedrosian Camille LEVP and Chief Medical OfficerApr 15Option Exercise55.005,000275,00044,139Apr 19 05:17 PM
Bedrosian Camille LEVP and Chief Medical OfficerApr 15Sale109.095,000545,45039,139Apr 19 05:17 PM
Huizenga Theodore AlanSVP, Controller and PAOMar 08Sale120.693,000362,07013,544Mar 09 12:37 PM
Harris ErikEVP & Chief Commercial OfficerMar 02Sale138.1670797,67927,813Mar 03 08:42 PM
Kassberg Thomas RichardCBO & EVPMar 01Sale138.174,572631,713107,181Mar 03 08:55 PM
Parschauer Karah HerdmanEVP and General CounselMar 01Sale138.173,970548,53530,227Mar 03 08:47 PM
Pinion John RichardSee RemarksMar 01Sale138.176,198856,37850,237Mar 03 08:48 PM
Huizenga Theodore AlanSVP, Controller and PAOMar 01Sale138.17732101,14016,544Mar 03 08:43 PM
Harris ErikEVP & Chief Commercial OfficerMar 01Sale138.172,470341,28028,520Mar 03 08:42 PM
Huang Dennis KarlEVP & Chief Tech Ops OfficerMar 01Sale138.184,255587,95640,761Mar 03 08:39 PM
Bedrosian Camille LEVP and Chief Medical OfficerMar 01Sale138.184,543627,75239,139Mar 03 08:37 PM
KAKKIS EMIL DPresident & CEOMar 01Sale141.8030,0004,254,0002,289,741Mar 03 08:36 PM
Aliski WilliamDirectorFeb 19Option Exercise97.857,500733,87573,204Feb 23 02:30 PM
Aliski WilliamDirectorFeb 19Sale149.017,5001,117,57565,704Feb 23 02:30 PM
Bedrosian Camille LEVP and Chief Medical OfficerJan 30Sale140.362,243314,82733,546Feb 02 04:28 PM
Bedrosian Camille LEVP and Chief Medical OfficerJan 15Option Exercise55.0025,0001,375,00060,789Jan 19 04:01 PM
Bedrosian Camille LEVP and Chief Medical OfficerJan 15Sale139.1825,0003,479,50035,789Jan 19 04:01 PM
Huizenga Theodore AlanSVP, Controller and PAOJan 07Option Exercise21.004,00084,00020,436Jan 08 07:05 PM
Huizenga Theodore AlanSVP, Controller and PAOJan 07Sale140.654,000562,60015,716Jan 08 07:05 PM
KAKKIS EMIL DPresident & CEOJan 04Sale136.9030,0004,107,0002,329,741Jan 05 06:45 PM